tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Immunic Buy Rating: Undervalued Next-Generation Oral MS Therapy with Key Phase III Catalysts and Strategic Partnership Upside
PremiumRatingsImmunic Buy Rating: Undervalued Next-Generation Oral MS Therapy with Key Phase III Catalysts and Strategic Partnership Upside
1M ago
Immunic Transfers Listing to Nasdaq Capital Market for Compliance
Premium
Company Announcements
Immunic Transfers Listing to Nasdaq Capital Market for Compliance
1M ago
Immunic price target lowered to $8 from $10 at H.C. Wainwright
Premium
The Fly
Immunic price target lowered to $8 from $10 at H.C. Wainwright
3M ago
Immunic initiated with a Buy at Roth Capital
PremiumThe FlyImmunic initiated with a Buy at Roth Capital
3M ago
IMUX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
IMUX Upcoming Earnings Report: What to Expect?
4M ago
Immunic’s Vidofludimus Calcium: A Promising MS Treatment with Unique Mechanism and Phase 3 Progress
Premium
Ratings
Immunic’s Vidofludimus Calcium: A Promising MS Treatment with Unique Mechanism and Phase 3 Progress
4M ago
Immunic Presents Promising Phase 2 Trial Results
PremiumCompany AnnouncementsImmunic Presents Promising Phase 2 Trial Results
5M ago
Immunic receives notice of allowance for vidofludimus calcium patent
Premium
The Fly
Immunic receives notice of allowance for vidofludimus calcium patent
5M ago
Promising Efficacy and Safety of Vidofludimus Calcium in MS Trials Reinforces Buy Rating
Premium
Ratings
Promising Efficacy and Safety of Vidofludimus Calcium in MS Trials Reinforces Buy Rating
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100